Biotech Values

[Mufaso]

Kallyope is exploring an IPO with JPMorgan:

Oral Weight-Loss Drug Developer Kallyope Exploring IPO
https://finance.yahoo.com/news/oral-weight-loss-drug-developer-194613314.html

Kallyope has two oral medicines in mid-stage clinical trials as treatments for both obesity and type 2 diabetes.

Kallyope, founded by three researchers at Columbia University, was valued at $1.14 billion after its last round of venture funding in 2022, according to Pitchbook. Its investors include Bill Gates and Abu Dhabi wealth fund Mubadala Investment Co. Franz Humer...

There are many well know Hormones having an impact on appetite and satiety. Kallyope is targeting with K-757 and K-833. Kallyope has disclosed that they target cholecystokinin (CCK) and Peptide YY (PYY).

I will be very interested in the prospectus if Kallyope makes it to market. I wouldn't be surprised if the current value of the company was well over the $1.14 billion it was valued at in 2022. Carmot was in the process of doing and IPO and never made it because Roche bought them.